Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[New anticoagulants in clinical practice].

Zoltán Boda1

  • 1Debreceni Egyetem, Orvos- és Egészségtudományi Centrum, Belgyógyászati Intézet, II. Belgyógyászati Klinika, Haemostaseologiai Tanszék. zboda@jaguar.unideb.hu

Orvosi Hetilap
|January 7, 2005
PubMed
Summary

New anticoagulants like pentasaccharide, ximelagatran, and recombinant human activated protein C (rh-APC) offer improved management for thrombotic and vascular disorders. These drugs provide specific inhibition of clotting factors, enhancing treatment efficacy and patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of regular prophylaxis with a plasma-derived von Willebrand factor/factor VIII concentrate with a 1:1 activity ratio in reducing heavy menstrual bleeding in girls/women with von Willebrand disease.

AJOG global reports·2025
Same author

Clinical and Molecular Characterization of Nine Novel Antithrombin Mutations.

International journal of molecular sciences·2024
Same author

von Willebrand factor/factor VIII concentrate (Wilate) prophylaxis in children and adults with von Willebrand disease.

Blood advances·2024
Same author

Vessel Wall-Derived Mesenchymal Stromal Cells Share Similar Differentiation Potential and Immunomodulatory Properties with Bone Marrow-Derived Stromal Cells.

Stem cells international·2020
Same author

Cellular Factor XIII, a Transglutaminase in Human Corneal Keratocytes.

International journal of molecular sciences·2019
Same author

A decade-long clinical experience on the prophylactic use of activated prothrombin complex concentrate in acquired haemophilia A: a case series from a tertiary care centre.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2018

Area of Science:

  • Pharmacology
  • Hematology
  • Vascular Medicine

Background:

  • Thrombotic and vascular disorders require effective anticoagulation.
  • Low molecular weight heparins (LMWHs) have significantly impacted venous thromboembolism management.
  • Novel anticoagulant agents are emerging with distinct mechanisms of action.

Purpose of the Study:

  • To summarize the qualities and clinical experiences of three new anticoagulants.
  • To highlight advancements in the management of thrombotic and vascular disorders.
  • To provide an overview of novel pharmacological interventions.

Main Methods:

  • Review of third-generation heparin (pentasaccharide) targeting Factor Xa.
  • Analysis of melagatran, a direct thrombin inhibitor, and its prodrug ximelagatran.

Related Experiment Videos

  • Evaluation of recombinant human activated protein C (rh-APC) for septic disseminated intravascular coagulation (DIC).

    • Main Results:

    • Pentasaccharide offers once-daily dosing due to its long half-life and specific FXa inhibition.
    • Ximelagatran represents the first orally active direct thrombin inhibitor.
    • rh-APC demonstrates advantages in managing septic DIC.

    Conclusions:

    • These novel anticoagulants provide diverse therapeutic options for thrombotic and vascular conditions.
    • Specific inhibition of clotting factors enhances treatment precision.
    • Clinical experiences suggest improved management strategies for various thromboembolic events.